The Comprehensive Center for Congenital Adrenal Hyperplasia, Institute for Pediatric Urology, Komansky Center for Children's Health, Department of Urology, New York-Presbyterian Hospital/Weill Cornell Medicine, New York, New York.
Division of Medical Genetics, Department of Pediatrics, New York-Presbyterian Hospital/Weill Cornell Medicine, New York, New York.
Ann N Y Acad Sci. 2017 Aug;1402(1):56-63. doi: 10.1111/nyas.13370. Epub 2017 Jun 22.
Mutations of CYP21A2 variably decrease 21-hydroxylase activity and result in a spectrum of disease expressions in patients with congenital adrenal hyperplasia (CAH). We examined the association between CYP21A2 mutations and virilization (Prader score) in females with CAH. The study population included 187 CAH females with fully characterized CYP21A2 mutations. One hundred fifty-eight patients were sorted into groups by expected enzyme activity (percent of normal activity) of the less severely affected allele: (A) null, 0%; (B) I2G, 1%; (C) I172N, 2%; and (D) V281L, >2%. We observed an inverse relationship between virilization and residual enzyme activity (P < 0.001). Subjects in group A or B had a significantly higher likelihood (unadjusted odds ratio: 16; P < 0.001) of developing severe virilization compared with those in group C. Surprisingly, 24% of group D patients, whose mutation is usually associated with nonclassical (NC) CAH, had severe virilization. Among subjects with the NC P30L mutation, 66% expressed unexpected virilization. Virilization, usually leading to extensive reconstructive surgery, is highly likely in patients with null or I2G mutations; however, NC mutations (P30L/V281L) may also lead to unexpected virilization. These findings have implications for prenatal counseling and highlight the need for additional investigations into other factors that influence virilization in CAH.
CYP21A2 突变可不同程度地降低 21-羟化酶的活性,导致先天性肾上腺皮质增生症(CAH)患者出现一系列疾病表现。我们研究了 CYP21A2 突变与 CAH 女性患者的男性化(Prader 评分)之间的关系。研究人群包括 187 名具有完全特征性 CYP21A2 突变的 CAH 女性患者。158 名患者根据受影响较轻等位基因的预期酶活性(正常活性的百分比)分为以下几组:(A)无功能,0%;(B)I2G,1%;(C)I172N,2%;和(D)V281L,>2%。我们观察到男性化与残留酶活性之间呈负相关(P<0.001)。与 C 组相比,A 组或 B 组的患者发生严重男性化的可能性显著更高(未经调整的优势比:16;P<0.001)。令人惊讶的是,24%的 D 组患者,其突变通常与非经典(NC)CAH 相关,发生严重男性化。在具有 NC P30L 突变的患者中,66%表现出意外的男性化。男性化通常导致广泛的重建手术,在无功能或 I2G 突变的患者中极有可能发生;然而,NC 突变(P30L/V281L)也可能导致意外的男性化。这些发现对产前咨询具有重要意义,并强调需要进一步研究影响 CAH 男性化的其他因素。